tiprankstipranks
Trending News
More News >

Atomo Diagnostics Issues New Shares to Bolster Market Position

Story Highlights
Atomo Diagnostics Issues New Shares to Bolster Market Position

Confident Investing Starts Here:

Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.

Atomo Diagnostics Limited announced the issuance of 46,929,731 fully paid ordinary shares to new and existing investors at an issue price of $0.0185 per share. This move, executed without disclosure under the Corporations Act, aims to strengthen the company’s financial position and support its operations in the competitive global diagnostic market. The announcement confirms Atomo’s compliance with relevant legal provisions and assures stakeholders of its transparency and adherence to regulatory standards.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Limited is an Australian-headquartered medical device company that provides unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The company’s patented devices enhance usability and reliability for rapid point-of-care (POC) and at-home testing, with products commercialized internationally. Atomo has supply agreements for testing applications targeting infectious diseases such as COVID-19, HIV, viral vs bacterial differentiation, and female health.

Average Trading Volume: 458,408

Technical Sentiment Signal: Buy

Current Market Cap: A$12.14M

See more data about AT1 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App